MAPT and Alzheimer disease: Cortical GFAP gene and protein expression were significantly upregulated in participants with a neuropathologically confirmed AD diagnosis at autopsy (all PFDR < 3.5e−4), but not in individuals positive for tau pathology and negative for amyloid pathology (all PFDR > 0.05).